

### UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Program Number	2024 P 3172-2
Program	Step Therapy
Medication	Methyldopa
P&T Approval Date	5/2023, 5/2024
Effective Date	8/1/2024

#### 1. Background:

Methyldopa is an aromatic-amino-acid decarboxylase inhibitor indicated for hypertension.

The American Heart Association recommends methyldopa as a widely established first-line option in the treatment of hypertension in pregnancy.

This program requires a member to try lower cost options prior to receiving coverage for methyldopa unless the patient is pregnant.

## 2. Coverage Criteria<sup>a</sup>:

A. Methyldopa will be approved based on <u>one</u> of the following criteria:

1. Patient is pregnant

#### -OR-

- 2. History of failure, contraindication or intolerance to <u>all</u> of the following (document name and date tried):
  - a. angiotensin-converting enzyme (ACE) inhibitor (e.g., lisinopril)
  - b. angiotensin receptor (ARB) blocker (e.g., valsartan)
  - c. calcium channel blocker (CCB; e.g. amlodipine)
  - d. diuretic (e.g. hydrochlorothiazide)

#### Authorization will be issued for 12 months.

<sup>a</sup> State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

#### 3. Additional Clinical Programs:

 Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.



# 4. References:

- 1. Methyldopa [package insert]. Conger, NY: Chartwell RX, LLC; November 2022.
- Garovic VD, Dechend R, Karumanchi SA, et al. Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement from the American Heart Association. Hypertension. 2022; 79: 321-e41.

Program	Step Therapy – Methyldopa
Change Control	
Date	Change
5/2023	New program.
5/2024	Annual review with no changes.

 $\ensuremath{\mathbb{C}}$  2024 UnitedHealthcare Services, Inc.